https://www.pharmaceutical-technology.com/data-insights/lonigutamab-ugodotin-acelyrin-net-present-value-2/
Lonigutamab Ugodotin is a monoclonal antibody commercialized by Acelyrin, with a leading Phase II program in Graves' Ophthalmopathy.
net present valuerisk adjustedcurrentvaluation
https://www.prnewswire.com/news-releases/acelyrin-inc-announces-300-million-series-c-financing-to-accelerate-phase-3-development-of-izokibep-a-unique-il-17a-inhibitor-to-treat-inflammatory-diseases-301622338.html
Financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic...
series c financingacelyrinincannouncesmillion